Veru announced the formation of a new Scientific Advisory Board to support the advancement of enobosarm, an oral novel selective androgen receptor modulator, to avoid muscle loss and augment fat loss when combined with a Glucagon-like peptide-1 receptor agonist drugs for potentially higher quality weight loss. The Scientific Advisory Board brings deep and complementary knowledge in metabolic diseases, obesity, weight management, muscle preservation and physical function in addition to significant experience in clinical research and in drug development. The members of Veru‘s new Scientific Advisory Board are: Dr. Caroline Apovian; Shalender Bhasin; Adrian Dobs; William Evans
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VERU:
- Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
- Veru reports Q1 revenue $2.1M vs. $2.5M last year
- Veru Reports Fiscal 2024 First Quarter Financial Highlights
- Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
- Veru announces FDA clearance of IND application for Phase 2b with enobosarm
